A first-in-human Phase I trial of the oral p-STAT3 inhibitor WP1066 in patients with recurrent malignant glioma

AIM: To ascertain the maximum tolerated dose (MTD)/maximum feasible dose (MFD) of WP1066 and p-STAT3 target engagement within recurrent glioblastoma (GBM) patients. PATIENTS & METHODS: In a first-in-human open-label, single-center, single-arm 3 + 3 design Phase I clinical trial, eight patients w...

Descripción completa

Detalles Bibliográficos
Autores principales: de Groot, John, Ott, Martina, Wei, Jun, Kassab, Cynthia, Fang, Dexing, Najem, Hinda, O'Brien, Barbara, Weathers, Shiao-Pei, Matsouka, Carlos Kamiya, Majd, Nazanin K, Harrison, Rebecca A, Fuller, Gregory N, Huse, Jason T, Long, James P, Sawaya, Raymond, Rao, Ganesh, MacDonald, Tobey J, Priebe, Waldemar, DeCuypere, Michael, Heimberger, Amy B
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Future Medicine Ltd 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9134932/
https://www.ncbi.nlm.nih.gov/pubmed/35575067
http://dx.doi.org/10.2217/cns-2022-0005

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9134932/
https://www.ncbi.nlm.nih.gov/pubmed/35575067
http://dx.doi.org/10.2217/cns-2022-0005

Ejemplares similares